CSL (OTCMKTS:CSLLY) Shares Gap Up – Here’s Why

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shares gapped up prior to trading on Tuesday. The stock had previously closed at $33.35, but opened at $35.64. CSL shares last traded at $34.37, with a volume of 1,765 shares traded.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Friday, August 7th. Royal Bank Of Canada upgraded shares of CSL from a “hold” rating to a “moderate buy” rating in a report on Tuesday, September 15th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

CSL Stock Up 3.0%

The company has a debt-to-equity ratio of 0.60, a current ratio of 2.21 and a quick ratio of 0.97. The firm’s 50 day simple moving average is $30.58 and its two-hundred day simple moving average is $24.28.

About CSL

CSL Limited (OTCMKTS:CSLLY) is an Australia-based biotechnology company that develops, manufactures and delivers medicines and vaccines. Its products address a range of serious and chronic conditions, including immune deficiencies, bleeding disorders, respiratory diseases, influenza and iron deficiency.

Through CSL Behring, the company produces plasma-derived and recombinant therapies, including immunoglobulins, albumin and treatments for hemophilia and hereditary angioedema. CSL also operates CSL Seqirus, a major influenza vaccine business that supplies seasonal and pandemic influenza vaccines, as well as other specialty products.